Reversal of high-fat diet-induced hepatic steatosis by n-3 LCPUFA: role of PPAR-α and SREBP-1c
Author
dc.contributor.author
Dossia, Camila G.
Author
dc.contributor.author
Tapia Opazo, Gladys
es_CL
Author
dc.contributor.author
Espinosa Escalona, Berta
es_CL
Author
dc.contributor.author
Videla Cabrera, Luis
es_CL
Author
dc.contributor.author
D'Espessailles Tapia, Amanda
es_CL
Admission date
dc.date.accessioned
2014-12-22T17:50:26Z
Available date
dc.date.available
2014-12-22T17:50:26Z
Publication date
dc.date.issued
2014
Cita de ítem
dc.identifier.citation
Journal of Nutritional Biochemistry 25 (2014) 977–984
en_US
Identifier
dc.identifier.other
dx.doi.org/10.1016/j.jnutbio.2014.04.011
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/129465
General note
dc.description
Artículo de publicación ISI
en_US
Abstract
dc.description.abstract
Nonalcoholic fatty liver disease is characterized by an abnormal accumulation of triacylglycerides in the liver in absence of significant alcohol consumption.
Under these conditions, it has been observed an impaired bioavailability of hepatic n-3 long-chain polyunsaturated fatty acids (LCPUFAs). The aim of this study
was to test the reversion of the prosteatotic and proinflammatory effects of high-fat diet (HFD) in the mouse liver by changing to normocaloric diet and n-3
LCPUFA supplementation. Male C57BL/6J mice were given either control diet (CD) or HFD for 12 weeks. Control and HFD groups were divided into subgroups
that continue with CD or subjected to CD plus n-3 LCPUFA for 8 additional weeks. After this time, blood and liver samples were taken and metabolic,
morphologic, oxidative stress, inflammatory and signaling parameters were analyzed. The dietary change from HFD to a normocaloric diet with n-3 LCPUFA
supplementation significantly reduced insulin resistance and liver steatosis when compared to switching HFD to normocaloric diet alone. In addition, HFDinduced
increases in adiposity, adipocyte enlargement and liver oxidative stress and inflammatory cytokine expression were suppressed by n-3 LCPUFA to
control values. Importantly, n-3 LCPUFA supplementation abolish HFD-induced enhancement in hepatic SREBP-1c/PPAR-α ratios, suggesting a change in the
metabolic status of the liver from a lipogenic condition to one favoring fatty acid oxidation and steatosis attenuation. These findings may provide the rational
basis for the use of normocaloric diets supplemented with n-3 LCPUFA in patients with liver steatosis.